Source:CanPharma
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Health House International’s (HHI) subsidiary entered an agreement to be the preferred supplier for cannabis flowers and extracts to more than 30 companies
  • The deal was penned between CanPharma CmbH and GWQ Service Plys AG, a company that represents 47 German public health insurance funds
  • Through the agreement, CanPharma will become a preferred supplier to more than 30 of the 47 insurance companies for a selection of its flowers and extracts
  • The agreement will begin as of January 1, 2022 through to November 30, 2023
  • Health House International is up 2.56 per cent, trading at 7.8 cents

Health House International’s (HHI) subsidiary has entered an agreement to be the preferred supplier for cannabis flowers and extracts to more than 30 companies.

The deal was penned between CanPharma CmbH and GWQ Service Plys AG, a company that represents 47 German public health insurance funds.

Through the agreement, CanPharma will become a preferred supplier to more than 30 of the 47 insurance companies that are shareholders in GWQ, for a selection of its own-branded flowers and extracts.

When doctors prescribe medicinal cannabis products for new patients that are insured with one of the GWQ affiliated insurance funds, they will be required to choose a product from a shortlist, if the patients are to be reimbursed.

CanPharma is one of the few German cannabis companies eligible for the scheme due to its GMP manufacturing licence.

“Following our decision to register a selection of our extracts and strains in the contract we hope it will increase the acceptance of cannabis as medicine by German prescribers, particularly once they see that the insurance companies endorse a reimbursement scheme,” CanPharma CEO and Health House Executive Director Henrik Sprengel said.

“In general, over one third of applications for reimbursement of medicinal cannabis are rejected and we hope that this new approach increases both the number of new prescriptions as well as the percentage reimbursed.”

The agreement will begin as of January 1, 2022 and last through to November 30, 2023.

Health House International was up 2.56 per cent, trading at 7.8 cents at the close of market on Wednesday.

HHI by the numbers
More From The Market Herald
BrainChip Holdings (ASX:BRN) -

" BrainChip (ASX:BRN) shares rise on another ‘breakout quarter’

BrainChip (ASX:BRN) has another "breakout quarter" for the three months leading up to December.

" Latin Resources (ASX:LRS) confirms Cloud Nine halloysite deposit ‘globally significant’

Latin Resources (ASX:LRS) confirms its Cloud Nine deposit in Western Australia is a "globally significant" halloysite…

" PolarX (ASX:PXX) gears up for fresh Nevada drilling program

Junior explorer PolarX (ASX:PXX) has today outlined its plans for a 3000-metre drilling program across its…

" Telix Pharmaceutical (ASX:TLX) first patient dosed in prostate cancer therapy program

Telix Pharmaceuticals Limited (ASX:TLX) has first patient dosed in its prostate-specific membrane antigen.